tbuckley/cabot-search huggingface dataset:
Avitaminosis Complicated by Cestodiasis; Case Report
Authors: J. A. Mcintosh
Journal: Annals of Internal Medicine (1930)

Article1 December 1930Avitaminosis Complicated by Cestodiasis; Case ReportJ. A. MCINTOSH, M.D., F.A.C.P.J. A. MCINTOSH, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-4-6-613 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAvitaminoses occur in man and other animals when diets poor or deficient in vitamins are eaten, but attention to protozoa and metazoa as "Vitamin robbers" in the intestinal tract capable of inducing avitaminosis in the host if the diet is below normal therein has not been recognized and given emphasis.We are familiar with the saying that a good appetite in the presence of malnutrition is suggestive of tape worm infestation, and such metazoa as the broad tape worm of the fish and the hookworm are known to cause secondary anemias, but they are not generally regarded as "Vitamin robbers"...References1 STITT ER: Practical Bacteriology, Blood Work, and Animal Parasitology, 7th edition, 1923, 714; Publishers, P. Blakiston's Son and Company. Google Scholar2 SIMON CE: A Manual of Clinical Diagnosis, etc., 10th edition, 1922, 457; Publisher, Lea and Febiger, Philadelphia. Google Scholar3 HALL MC: The Relations of Human and Veterinary Parasitology, Journal A. M. A., April 19, 1930, Vol. 94, No. 16, 1189. CrossrefGoogle Scholar4 SHERMANSPOHN HCA: A Critical Investigation and an Application of the Rat Growth Method for the Study of Vitamin B, Jour. Amer. Chem. Soc., 1923, Vol. 45, No. 11, 2719. CrossrefGoogle Scholar5 GOLDBERGERWHEELERLILLIEROGERS JGARDLM: A Further Study of Butter, Fresh Beef, and Yeast as Pellagra Preventives, with Consideration of the Relation of Factor P-P of Pellagra (and Black Tongue of Dogs) to Vitamin B. U. S. Public Health Reports, 1926, Vol. 141, No. 8, 297. CrossrefGoogle Scholar6 SMITH SL: Vitamins in Food Materials. U. S. Dept. Agric., Circular 1929, No. 84. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Memphis, Tenn.*Read before the Memphis and Shelby County Medical Society April 15, 1930. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1930Volume 4, Issue 6Page: 613-619KeywordsAnemiaDietHookwormsMalnutritionVitamins ePublished: 1 December 2008 Issue Published: 1 December 1930 PDF downloadLoading ...
Abstract 18667: Anti-atherosclerotic Effect of CER-001, an Engineered HDL-mimetic, in the High-fat Diet-fed LDLr Knockout Mice
Authors: Marine Goffinet, Claudine Tardy, Alice Bluteau, Nadia Boubekeur, Rudi Baron, Constance Keyserling, Ronald Barbaras, Narendra Lalwani, Jean-Louis Dasseux
Journal: Circulation (2012)

CER-001 is an engineered HDL-mimetic, comprised of recombinant human ApoA I and phospholipid, exhibiting properties of nascent pre-ß HDL. Intravenous infusion of CER-001 promotes reverse lipid transport by causing rapid mobilization of cholesterol in animals, including in man. Previous studies have shown that CER-001 induced cholesterol efflux from macrophages similar to HDL3 in vitro, enhanced LCAT activity, and exhibited anti-inflammatory response similar to natural HDL. The aim of this study was to evaluate the effect of CER-001 on atherosclerotic plaques in high-fat diet-fed LDL-receptor -/- mice. Mice on high-fat diet for 10 weeks were given CER-001, 10 mg/Kg, intravenously. Aortic plaques were evaluated by immunohistochemistry following 5 or 10 doses given every second day. CER-001 caused 22.5% (p=0.02) and 32% (p= 0.009) reductions in plaque size, and 14% (p=0.08) and 23% (p=0.03) reductions in lipid content following a treatment regimen of 5 and 10 doses, respectively. Also, there was an 80% reduction in macrophage content in the plaque following 5 doses, as shown by F4/80 staining (p=0.0001), suggesting decreased inflammation. These data suggest that CER-001, an HDL-mimetic, could be a suitable therapeutic for the treatment of atherosclerosis and associated vascular complications, including in familial hypercholesterolemia patients.
When will Molecular Fingerprints Dominate Cancer Treatment Selection
Authors: Martine Piccart-Gebhart, Phuong Dinh, Christos Sotiriou
Journal: Clinical Cancer Research (2007)

CN05-03   Historically, the selection of adjuvant systemic therapy in early breast cancer has relied on risk assessment incorporating both patient-related and tumor-related prognostic factors. These prognostic factors serve to characterize the background level of risk of relapse against which the benefits and burdens of adjuvant therapies are weighed. Tumor-related factors include lymph node involvement, tumor size, tumor grade and estrogen-receptor (ER) and HER-2 status.  With the advent of microarray technology, unprecedented opportunities have become available for performing comprehensive molecular and genetic profiling of breast cancer. This has resulted in a) a new molecular classification of breast cancer into clinically relevant subtypes, b) various molecular “prognostic” signatures that have performed, as well as, if not better than, traditional clinico-pathological prognostic factors in predicting clinical outcome, and c) a number of molecular signatures that bear the exciting promise of being able to identify subsets of patients who are particularly sensitive to a given drug or regimen of drugs (“predictive” signatures).  Encouragingly, the various prognostic classifiers have proven to be highly concordant with each other in retrospective validation studies, despite having only a few overlapping genes. Work by our group has shown that one reason for this may be that these multigene predictors reflect similar oncogenic pathways where genes involved in proliferation and the cell-cycle represent the common driving force.  The potential for these molecular signatures is vast but their entry into the clinic can only take place after prospective validation for robustness and reproducibility. Many of the studies to date, in fact, have been small retrospective series using different patient populations, different microarray platforms and different statistical models. The results of large prospective, randomized trials such as MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy) and TAILORx (Trial Assigning IndividuaLized Options for Treatment, will provide the much needed Level 1 evidence for at least two of the multigene predictors, facilitating the shift from “bench-to-bedside”. However,  validation strategies for “predictive” signatures still lag behind. To help address this issue, we will present a potential new model for accelerating that “bench-to-bedside” shift.  Once validated, the ultimate goal for these molecular signatures is to be part of an integrative decision-making algorithm based on multiple levels and sources of prognostic and predictive data. Alongside traditional clinico-pathological risk parameters, molecular tools such as gene expression profiles and developments in functional proteomics will enable us to treat patients with the therapies that are most likely to confer individual benefit and, equally important, to spare patients from unnecessary treatments and associated toxicities.
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
Authors: Sylvain Pilorge, Sophie Rigaudeau, Florence Rabian, Clémentine Sarkozy, Anne L. Taksin, Hassan Farhat, Fathia Merabet, Stéphanie Ghez, Victoria Raggueneau, Christine Terré, Isabelle Garcia, Aline Renneville, Claude Preudhomme, Sylvie Castaigne, Philippe Rousselot
Journal: American Journal of Hematology (2013)

Gemtuzumab ozogamicin (fGO), a humanized anti‐CD33 monoclonal antibody linked to calicheamicin in combination with intensive chemotherapy gives high response rates in adult acute myeloid leukemia (AML) patients in relapse. However, reduced intensity chemotherapy in combination with fractionated GO has not been tested in aged relapsing patients. Patients from our institution with CD33+ AML aged 55 years or more in first late relapse (≥6 months) were proposed participation in a GO compassionate use program. Induction therapy consisted in fractionated GO (fGO; 3 mg/m 2 , days 1, 4, 7) with standard‐dose cytarabine (200 mg/m 2 /day, 7 days). Patients were consolidated with two courses of GO and intermediate dose cytarabine. Twenty‐four patients (median age 68 years) received fGO with cytarabine. Median follow‐up was 42 months. The response rate was 75%, including complete remission (CR) in 16 patients and CR with incomplete platelet recovery (CRp) in two patients. Two‐year overall survival (OS) was 51% (95% CI: 28–69) and 2 years relapse‐free survival (RFS) was 51% (95%CI: 25–72). Duration of second CR (CR2) was longer than first CR (CR1) in 9 out of 18 patients. Minimal residual disease (MRD) was negative in evaluable patients in CR2, particularly in NPM1 mutated cases. Toxicity was in line with that of the same fractionated single agent GO schedule. Fractionated GO with low intensity chemotherapy produced high response rates and prolonged CR2 in aged AML patients in first late relapse. Am. J. Hematol. 89:399–403, 2014. © 2013 Wiley Periodicals, Inc.
Improved Care for Neglected Population Must Be "Rule Rather Than Exception"
Authors: Rebecca Voelker
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
2K-CAP (a novel bis-benzylisoquinoline alkaloid) decreases prostate-specific antigen and induces Go/G1 cell cycle growth arrest of prostate carcinoma cells: implications for prostate cancer intervention
Authors: Sweaty Koul, Hari K. Koul
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

5881 

Prostate cancer is the second leading cause of cancer deaths in men. Reduction in serum prostate-specific antigen (PSA) levels has been proposed as an endpoint biomarker for human prostate cancer intervention. We investigated the effects of 2K-CAP, a novel derivative of tetrandrine (an active constituent of Chinese herb S. tetrandra) on PSA secretion and cell growth and proliferation in LNCaP cells, a line of hormone sensitive prostate cancer cells. Treatment of LNCaP cells with 2K-CAP resulted in significant decrease in PSA synthesis and secretion. Treatment of cells with charcoal stripped serum and 5α-dihyroxy testosterone showed that 2K-CAP treatment inhibited androgen stimulated PSA secretion and down regulation of androgen receptor levels. 2K-CAP also suppressed the growth and proliferation of LNCaP cells. These effects of 2K-CAP on inhibition of growth and proliferation were time ( 24-96h) and concentration (5-20 μM) dependent. We also show that 2K-CAP treatment inhibited growth and proliferation of LNCaP cells stimulated by androgens as well as complete Fetal Calf Serum. These results demonstrate that 2K-CAP treatment had profound effect on androgen dependent as well as growth factor stimulated growth and proliferation of prostate cancer cells. 2K-CAP treatment resulted in increase in Rip/p21 levels with no effect on p27/Kip. Cell Cycle analysis revealed that 2 K-CAP treatments increased the number of cells in Go/G1-phase of the cell cycle, consistent with G1/Go arrest. Taken together these studies demonstrate that 2K-CAP causes growth arrest of LNCaP cells by inhibiting cell cycle in Go/G1 phase, and inhibiting PSA synthesis and secretion. These results demonstrate that 2K-CAP as a potential agent for intervention of prostate cancer.
Adenosine Deaminase Deficiency in Adults
Authors: Hulya Ozsahin, Francisco X. Arredondo-Vega, Ines Santisteban, Hanspeter Fuhrer, Peter Tuchschmid, Wolfram Jochum, Adriano Aguzzi, Howard M. Lederman, Amy Fleischman, Jerry A. Winkelstein, Reinhard A. Seger, Michael S. Hershfield
Journal: Blood (1997)
A memorable patient: Suffering in silence
Authors: M. Khan
Journal: BMJ (2001)

In less developed societies where poverty, illiteracy, and deeply ingrained cultural beliefs coexist, human distress can take on an unimaginable garb.

I saw her in the mental health clinic in Orangi, one of the many slum areas of Karachi, Pakistan's largest city. She was barely 5ft tall and, walking with a slight droop of the shoulders, looked shorter still. The doctors could not find any reason for her complaints—headaches, palpitations, weakness, appetite, and weight loss. Various analgesics, vitamins, tranquillisers, and antidepressants had had no effect. X rays, endoscopies, blood and urine tests were all normal.

Married with two grown up sons, she had no other living relatives. I could not understand the cause of her symptoms.

I ask about her relationship with her husband. “It's …
Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan
Authors: H Nishiura, C Castillo-Chavez, M Safan, G Chowell
Journal: Eurosurveillance (2009)

On 16 May 2009, Japan confirmed its first three cases of new influenza A(H1N1) virus infection without a history of overseas travel, and by 1 June, 361 cases, owing to indigenous secondary transmission, have been confirmed. Of these, 287 cases (79.5%) were teenagers (i.e. between 10 and 19 years of age). The reproduction number is estimated at 2.3 (95% confidence interval: 2.0, 2.6). The average number of secondary transmissions involving minors (those under 20 years of age) traced back to infected minors is estimated at 2.8. That is, minors can sustain transmission even in the absence of adults. Estimates of the effective reproduction number Rt moved below 1 by 17 May. Active surveillance and public health interventions, including school closures most likely have contributed to keeping Rt below one.
Abstract 16551: Throttle and Brake - A Novel Therapeutic Strategy in Post-Ischemic Acute Heart Failure by Combined Use of Dobutamine and Ivabradine
Authors: Jens P Bakkehaug, Torvind Næsheim, Eirik Engstad, Anders Kildal, Truls Myrmel, Ole J How
Journal: Circulation (2014)

Introduction:  Compensatory tachycardia can potentially be deleterious in ischemic and post ischemic acute heart failure. We tested a therapeutic strategy by combining inotropic support and slowing the sinus node using ivabradine.   Methods:  In an open-chest pig model (n=12) with left ventricular (LV) ischemic reperfusion injury, cardiac performance was assessed by LV pressure catheter and sonometric crystals for LV volumetry. Coronary flow probes and blood samples from the coronary sinus supplied data for myocardial oxygen combustion (MVO2).   Results:  Dobutamine (5 ug/kg/min) restored cardiac output in the post ischemic heart by increasing heart rate from 102 ± 21 to 131±16 bpm. Adding ivabradine (0.5 mg/kg) to dobutamine-support slowed heart rate back to 100 ± 9 bpm and increased stroke volume (SV) from 29 ± 5 to 35 ± 3 ml while maintaining cardiac output (CO) and mean arterial pressure (MAP).  Ivabradine had a neutral effect on post ischemic LV energetics compared to dobutamine alone at a wide range of workloads.   Conclusion:  There was no surplus oxygen consumption in post-ischemic hearts when combining ivabradine with dobutamine , Furthermore, addition of ivabradine to dobutamine restored the hemodynamics to pre-ischemic levels by reducing the heart rate and increasing the SV and stroke work while maintaining MAP and CO.
Abstract MP52: Beyond Body Mass Index: A Population-Based Comparison Demonstrates Advantages of Abdominal Anthropometry for Identifying Cardiometabolic Dysfunctions
Authors: Henry S Kahn, Kai M Bullard
Journal: Circulation (2015)

Background: A weight-based adiposity indicator (body mass index; BMI, kg/m 2 ) is often reported for adults. Indicators based on sagittal abdominal diameter (SAD) or waist circumference have also identified cardiometabolic risk. Aim: Compare SAD/height ratio (SADHtR) or waist/height ratio (WHtR) with BMI for identifying risks in a representative sample of non-elderly adults without diagnosed diabetes. Outcome dysfunctions were Dysglycemia (glycated hemoglobin ≥5.7%), HyperNonHDLc (non-HDL-cholesterol ≥160 mg/dL or taking cholesterol meds), Hypertension (SBP ≥140 or DBP ≥90 or taking blood-pressure meds) and HyperALT (alanine transaminase ≥75 th %ile [sex-specific p75]). Methods: Non-pregnant adults (ages 20-64 y; N=3,071) in the 2011-2012 US National Health and Nutrition Examination Survey provided conventional anthropometry and supine SAD (by sliding - beam caliper). Sample weighting permitted estimation of population characteristics, including odds ratios (ORs) associated with each adiposity indicator (logistic regression models adjusted for age, sex and ancestry). For each dysfunction, we compared the ORs for 3 indicators after rescaling them to the indicator’s sex-specific, interquartile range. Results: The population distributions (mean; p25, p75) of indicators among men were: SADHtR (0.129; 0.112, 0.144), WHtR (0.564; 0.505, 0.613), and BMI (28.2; 24.2, 31.0). Among women they were: SADHtR (0.131; 0.112, 0.148), WHtR (0.580; 0.510, 0.636), and BMI (28.3; 23.4, 31.7). Dysfunction prevalence ranged from 21.9% (Dysglycemia in women) to 42.4% (HyperNonHDLc in men). To identify HyperNonHDLc, Hypertension and HyperALT (but not Dysglycemia), the ORs were highest for SADHtR and lowest for BMI. When SADHtR entered models simultaneously with BMI, the ORs associated with BMI no longer contributed to identification of HyperNonHDLc, Hypertension, or HyperALT (Figure). Conclusions: Among US adults, the SADHtR provides low-cost estimation of cardiometabolic risk independently of BMI.
Suppression of leukemia growth in vivo by a novel anti-FLT3 antibody-auristatin conjugate
Authors: Yiwen Li, Hongli Li, Mei-Nai Wang, Rajiv Bassi, Venkat Mangalampalli, Dale L. Ludwig, Paul Balderes, Larry Witte, Zhenping Zhu, Damon Meyer, Angelyn Larkin, Peter Senter, Peter Bohlen, Daniel J. Hicklin
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

6181 

The class III receptor tyrosine kinase FLT3 is an attractive therapeutic target as it is overexpressed in blasts of ∼90% of acute myelogenous leukemia (AML) and the majority of B-lymphoid leukemia patients. Internal tandem duplications (ITDs) in the juxtamembrane region and point mutations in the kinase domain of FLT3 are found in ∼37% of AML patients and are associated with a poor prognosis. We have recently developed a fully human, high affinity monoclonal antibody (EB10) which is readily internalized upon binding to FLT3 receptor on human leukemia cells. In the present study, a novel auristatin conjugate of the anti-FLT3 antibody (EB10-MMAF) was prepared using a dipeptide linker that allows for drug release inside the lysosomes of antigen-positive cells. The MMAF conjugates were stable in buffers and plasma. EB10-MMAF (drug/antibody ratio = 8) retained the binding affinity and internalizing capability of EB10. The conjugate was highly potent, and selectively inhibited the growth of FLT3-expressing leukemia cells with an IC50 of 0.19 nM and 0.08 nM for MV4;11 and BaF3-ITD cells (both positive for FLT3-ITD), 1.11 nM, 6.18 nM and 1.82 nM for REH, EOL-1, EM3 cells (all three positive for wild-type FLT3), and 135 nM for JM1 (negative for FLT3). An MMAF conjugate with a control antibody was not active in these cell lines (IC50s > 5.9 uM). Flow cytometric analysis with annexin V indicated that EB10-MMAF treatment induced apoptosis of leukemia cells in vitro . In vivo treatment with EB10-MMAF strongly inhibited leukemia growth and prolonged survival of mice in both EOL-1 (mean survival time ∼81.0 +/− 46.8 days for the 3 mg/kg group compared to 41.5+/−15 days for the untreated group) and BaF3-ITD (mean survival time ∼91.5 +/− 39.5 days for the 5 mg/kg group compared to 32.8 +/− 5.2 days for the untreated group) leukemia models. In summary, immunoconjugates composed of a fully human anti-FLT3 antibody and a potent auristatin drug may provide a valuable therapeutic approach for AML and other FLT3-positive leukemias. In summary, immunoconjugates composed of a fully human anti-FLT3 antibody and a potent auristatin drug may provide a valuable therapeutic approach for AML and other types of FLT3-positive leukemia.
Abstract 18335: Reversing Right Ventricular(RV) and Left Ventricular(LV) Pace Sense(PS) Leads in the Implantable Cardioverter Defibrillator(ICD) Header in Patients With the Medtronic 6949 ICD Lead and Bipolar LV Lead: A Method to Avert Consequences of the Common Failure Modes
Authors: Rusell Reeves
Journal: Circulation (2013)

Background: Failure of the ring electrode of an implanted Medtronic Sprint Fidelis (6949 family) ICD lead commonly results in unnecessary shocks and can also lead to failure to pace. Placing a different PS lead will obviate this failure mode. We propose using a bipolar LV lead as the PS lead by connecting it to RV port, and connecting the PS part of the Fidelis lead to the LV port. Methods: Between 10/07 and 6/10 we identified 12 patients with Medtronic 6949 ICD leads and a Bipolar LV lead who underwent device procedures. All but one of the LV leads were Medtronic 4194. Criteria for swapping leads include: 1)adequate sensing by the LV lead; 2)no phrenic stimulation when pacing the LV lead; 3)no large T wave on the LV lead; 4) no failure of tip electrode or RV shocking coil of the ICD lead. The ring pacing electrode is not used, and the SVC coil is rarely needed for defibrillation. The ability to program around phrenic stimulation by reprogramming the LV pacing vector is lost. The LV port is programmed to pace Tip to RV coil. This effectively paces the ICD lead from tip to its coil. The RV port sensing configuration is left bipolar. Any LV-RV timing offset needs to be reversed. We turn off Ventricular Sense Response and LV lead capture management. Results: The first patient was not swapped but led to the criteria for future procedures. One patient had an LV R wave of 2.6 mv (threshold 3.5V) and was not swapped. Ten patients underwent the swap. Three had failure of the ring electrode of the Fidelis lead at the time of the procedure. Of the 10 patients, the LV R wave was 18.6 +- 8.2(mean +-SD), pacing threshold 1.26 +- .71, and RV R wave 19.8+-7.0, threshold 0.65+-.15. The patient who had a bipolar lead from another manufacturer developed noise on the LV lead and required reoperation. Another had T wave sensing when BiV paced and received a shock from double counting. This system is functioning after reprogramming. Thus 9 of the 10 have functioned satisfactorily. Conclusion: Placing a bipolar LV lead into the RV PS port, and the Fidelis pace/sense connector into the LV port with appropriate reprogramming may be an alternative to either lead extraction or placing a new PS lead or ICD lead in many CRT patients at the time of ICD generator change.